Consolidated total income up 13%; robust anti-diabetic sales, new product pipeline, expanded coverage of cardiologists support better numbers...

https://www.business-standard.com/article/companies/eris-lifesciences-q4-pat-up-21-yoy-on-strong-show-by-superspecialty-biz-121051300901_1.html

#business-standard